Cited by 467Opioid Use Disorder TreatmentSubstance Abuse Treatment and OutcomesPain Management and Opioid Use

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial

Kakko, Johan, Svanborg, Kerstin Dybrandt, Kreek, Mary Jeanne, Heilig, Markus·2003·The Lancet

Open this paper in CoChat — free account

Abstract

Background The partial opiate-receptor agonist buprenorphine has been suggested for treatment of heroin dependence, but there are few long-term and placebo-controlled studies of its effectiveness. We aimed to assess the 1-year efficacy of buprenorphine in combination with intensive psychosocial therapy for treatment of heroin dependence.Methods 40 individuals aged older than 20 years, who met DSM-IV criteria for opiate dependence for at least 1 year, but did not fulfil Swedish legal criteria for methadone maintenance treatment were randomly allocated either to daily buprenorphine (fixed dose 16 mg sublingually for 12 months; supervised daily administration for a least 6 months, possible take-home doses thereafter) or a tapered 6 day regimen of buprenorphine, thereafter followed by placebo. All patients participated in cognitive-behavioural group therapy to prevent relapse, received weekly individual counselling sessions, and submitted thrice weekly supervised urine samples for analysis to detect illicit drug use. Our primary endpoint was 1-year retention in treatment and analysis was by intention to treat.Findings 1-year retention in treatment was 75% and 0% in the buprenorphine and placebo groups, respectively (p=0.0001; risk ratio 58.7 [95% CI 7.4-467.4]). Urine screens were about 75% negative for illicit opiates, central stimulants, cannabinoids, and benzodiazepines in the patients remaining in treatment.Interpretation The combination of buprenorphine and intensive psychosocial treatment is safe and highly efficacious, and should be added to the treatment options available for individuals who are dependent on heroin.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(03)12600-1

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The Fifth Edition of the Addiction Severity Index.
Mclellan, A., Kushner, H., Metzger, D., Peters, R., Smith, I. E., Grissom, G. R., Pettinati, H., & Argeriou, M. (1992) · Journal of Substance Abuse Treatment · doi:10.1016/0740-5472(92)90062-s · Cited by 4,280
The Effects of Psychosocial Services in Substance Abuse Treatment
McLellan, A. T. (1993) · JAMA · doi:10.1001/jama.1993.03500150065028 · Cited by 827
A Comparison of Levomethadyl Acetate, Buprenorphine, and Methadone for Opioid Dependence
Johnson, R. E., Chutuape, M. A., Strain, E. C., Walsh, S. L., Stitzer, M. L., & Bigelow, G. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011023431802 · Cited by 623
Relapse prevention. An overview of Marlatt's cognitive-behavioral model.
(1999) · PubMed Central · Cited by 585
Effective Medical Treatment of Opiate Addiction
Addiction, N. C. D. P. O. E. M. T. O. O. (1998) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.280.22.1936 · Cited by 577
A Controlled Trial of Buprenorphine Treatment for Opioid Dependence
Johnson, R. E. (1992) · JAMA · doi:10.1001/jama.1992.03480200058024 · Cited by 567
Relapse prevention: introduction and overview of the model
Marlatt, G. A., & George, W. H. (1984) · British Journal of Addiction · doi:10.1111/j.1360-0443.1984.tb03867.x · Cited by 476
Relapse Prevention: Introduction and Overview of the Model
Marlatt, G. A., & George, W. H. (1984) · British Journal of Addiction · doi:10.1111/j.1360-0443.1984.tb00274.x · Cited by 475
Methadone Maintenance vs 180-Day Psychosocially Enriched Detoxification for Treatment of Opioid Dependence: A Randomized Controlled Trial
Sees, K. L., Delucchi, K. L., Masson, C., Rosen, A., Clark, H. W., Robillard, H., Banys, P., & Hall, S. M. (2000) · JAMA · doi:10.1001/jama.283.10.1303 · Cited by 415 · cited 1×
“5 By contrast, a large amount of published work shows that maintenance treatment with methadone, a long acting full opiate receptor agonist, can greatly increase adherence to treatment, lessen illicit drug use, and reduce mortality.”
Background
Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial
Ling, W., Charuvastra, C., Collins, J. F., Batki, S., Brown, L. S., Kintaudi, P., Wesson, D. R., Mcnicholas, L., Tusel, D. J., Malkerneker, U., et al. (1998) · Addiction · doi:10.1046/j.1360-0443.1998.9344753.x · Cited by 402

Show all 32 references

Research works printed but not linked: 1

Compton, 1994, What dose of buprenorphine reduces opiate use? a double-blind dose-ranging study, NIDA Res Monogr, 153, 138

Sorted by citations

Items 101–200 of 467

Attending physicians' and residents' attitudes and beliefs about prescribing buprenorphine at an urban teaching hospital.
Cunningham, C. O., Sohler, N., McCoy, K., & Kunins, H. V. (2006) · PubMed · Cited by 60
A Clinical Trial Comparing Tapering Doses of Buprenorphine With Steady Doses for Chronic Pain and Coexistent Opioid Addiction
Blondell, R. D., Ashrafioun, L., Dambra, C. M., Foschio, E. M., Zielinski, A. L., & Salcedo, D. M. (2010) · Journal of Addiction Medicine · doi:10.1097/adm.0b013e3181ba895d · Cited by 59
Stress-related neuropeptides and alcoholism: CRH, NPY, and beyond
Ciccocioppo, R., Gehlert, D. R., Ryabinin, A. E., Kaur, S., Cippitelli, A., Thorsell, A., Lê, A. D., Hipskind, P. A., Hamdouchi, C., Lu, J., et al. (2009) · Alcohol · doi:10.1016/j.alcohol.2009.08.003 · Cited by 58
Self-citation
Methods of Detoxification and Their Role in Treating Patients With Opioid Dependence
O’Connor, P. G. (2005) · JAMA · doi:10.1001/jama.294.8.961 · Cited by 58
Prescription of Heroin for the Management of Heroin Dependence
Lintzeris, N. (2009) · CNS Drugs · doi:10.2165/00023210-200923060-00002 · Cited by 57
Management of opioid addiction with opioid substitution treatments: beyond methadone and buprenorphine
Noble, F., & Marie, N. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00742 · Cited by 56
Narrative Review: Buprenorphine for Opioid-Dependent Patients in Office Practice
Sullivan, L. E., & Fiellin, D. A. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-9-200805060-00006 · Cited by 55
Relative effectiveness of medications for opioid-related disorders: A systematic review and network meta-analysis of randomized controlled trials
Lim, J., Farhat, I., Douros, A., & Panagiotoglou, D. (2022) · PLoS ONE · doi:10.1371/journal.pone.0266142 · Cited by 59
Predictors of Abstinence: National Institute of Drug Abuse Multisite Buprenorphine/Naloxone Treatment Trial in Opioid-Dependent Youth
Subramaniam, G., Warden, D., Minhajuddin, A., Fishman, M. J., Stitzer, M. L., Adinoff, B. H., Trivedi, M. H., Weiss, R. D., Potter, J. S., Poole, S. A., et al. (2011) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2011.07.010 · Cited by 54
Network therapy: Decreased secondary opioid use during buprenorphine maintenance
Galanter, M. S., Dermatis, H., Glickman, L., Maslansky, R. A., Sellers, M. B., Neumann, E., & Rahman-Dujarric, C. (2004) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2004.03.002 · Cited by 54
Opioid agonist treatment for people who are dependent on pharmaceutical opioids
Nielsen, S., Tse, W. C., & Larance, B. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011117.pub3 · Cited by 50
Impact of Chronic Pain on Treatment Prognosis for Patients with Opioid Use Disorder: A Systematic Review and Meta-analysis
Dennis, B. B., Bawor, M., Naji, L., Chan, C. K., Varenbut, J., Paul, J., Varenbut, M., Daiter, J., Plater, C., Paré, G., et al. (2015) · Substance Abuse Research and Treatment · doi:10.4137/sart.s30120 · Cited by 50
Opioid Dependence: Rationale for and Efficacy of Existing and New Treatments
Fiellin, D. A., Friedland, G. H., & Gourevitch, M. N. (2006) · Clinical Infectious Diseases · doi:10.1086/508180 · Cited by 49
The clinical efficacy and abuse potential of combination buprenorphine–naloxone in the treatment of opioid dependence
Mammen, K., & Bell, J. R. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903213405 · Cited by 48
Total Joint Arthroplasty in Patients Taking Methadone or Buprenorphine/Naloxone Preoperatively for Prior Heroin Addiction: A Prospective Matched Cohort Study
Hansen, L. E., Stone, G. L., Matson, C., Tybor, D. J., Pevear, M. E., & Smith, E. L. (2016) · The Journal of Arthroplasty · doi:10.1016/j.arth.2016.01.032 · Cited by 49
Challenges in the adoption of new pharmacotherapeutics for addiction to alcohol and other drugs
Saxon, A. J., & McCarty, D. W. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.06.014 · Cited by 49
Office-Based Buprenorphine Treatment for Opioid-Dependent Patients
McCance‐Katz, E. F. (2004) · Harvard Review of Psychiatry · doi:10.1080/10673220490905688 · Cited by 47
Overdose Prevention Through Medical Treatment of Opioid Use Disorders
Volkow, N. D., & Wargo, E. M. (2018) · Annals of Internal Medicine · doi:10.7326/m18-1397 · Cited by 47
Update on the clinical use of buprenorphine: in opioid-related disorders.
Ducharme, S., Fraser, R., & Gill, K. (2012) · PubMed Central · Cited by 46
Identifying Opioid Use Disorder in the Emergency Department: Multi-System Electronic Health Record–Based Computable Phenotype Derivation and Validation Study
Chartash, D., Paek, H., Dziura, J. D., Ross, B. K., Nogee, D., Boccio, E., Hines, C., Schott, A. M., Jeffery, M. M., Patel, M. D., et al. (2019) · JMIR Medical Informatics · doi:10.2196/15794 · Cited by 44
Identification and Management of Opioid Use Disorder in Primary Care: an Update
Donroe, J. H., Bhatraju, E. P., Tsui, J. I., & Edelman, E. J. (2020) · Current Psychiatry Reports · doi:10.1007/s11920-020-01149-0 · Cited by 46
A qualitative study of emergency department patients who survived an opioid overdose: Perspectives on treatment and unmet needs
Hawk, K. F., Grau, L. E., Fiellin, D. A., Chawarski, M. C., O’Connor, P. G., Cirillo, N., Breen, C., & D’Onofrio, G. (2020) · Academic Emergency Medicine · doi:10.1111/acem.14197 · Cited by 46
Improved Quality of Life, Clinical, and Psychosocial Outcomes Among Heroin-dependent Patients on Ambulatory Buprenorphine Maintenance
Ponizovsky, A. M., Margolis, A., Heled, L., Rosca, P., Radomislensky, I., & Grinshpoon, A. (2009) · Substance Use & Misuse · doi:10.3109/10826080902873010 · Cited by 45
HUMAN GENETIC STUDY: Association analysis of genes encoding the nociceptin receptor (OPRL1) and its endogenous ligand (PNOC) with alcohol or illicit drug dependence
Xuei, X., Wetherill, L. F., Almasy, L. A., Bierut, L. J., Tischfield, J. A., Schuckit, M. A., Nürnberger, J. I., Foroud, T., & Edenberg, H. J. (2007) · Addiction Biology · doi:10.1111/j.1369-1600.2007.00082.x · Cited by 44
State Responses to the Opioid Crisis
Parker, A. M., Strunk, D., & Fiellin, D. A. (2018) · The Journal of Law Medicine & Ethics · doi:10.1177/1073110518782946 · Cited by 44
The Potential Role of Buprenorphine in the Treatment of Opioid Dependence in HIV-Infected Individuals and in HIV Infection Prevention
Altice, F. L., Sullivan, L. E., Smith-Rohrberg, D., Basu, S., Stancliff, S., & Eldred, L. J. (2006) · Clinical Infectious Diseases · doi:10.1086/508181 · Cited by 44
Were the changes to Sweden's maintenance treatment policy 2000–06 related to changes in opiate‐related mortality and morbidity?
Romelsjö, A., Engdahl, B., Stenbacka, M., Fugelstad, A., Davstad, I., Leifman, A., & Thiblin, I. (2010) · Addiction · doi:10.1111/j.1360-0443.2010.02999.x · Cited by 43
At the crossroads: HIV prevention and treatment for people who inject drugs in U kraine
Bojko, M. J., Дворяк, С., & Altice, F. L. (2013) · Addiction · doi:10.1111/add.12243 · Cited by 44
Comparison of Buprenorphine Treatment for Opioid Dependence in 3 Settings
Miotto, K. A., Hillhouse, M. P., Donovick, R. A., Cunningham‐Rathner, J., Charuvastra, C., Torrington, M., Esagoff, A. E., & Ling, W. W. (2011) · Journal of Addiction Medicine · doi:10.1097/adm.0b013e318233d621 · Cited by 42
Emergency Department Treatment of Opioid Addiction: An Opportunity to Lead
Martin, A., Mitchell, A., Wakeman, S. E., White, B., & Raja, A. S. (2017) · Academic Emergency Medicine · doi:10.1111/acem.13367 · Cited by 43
Suboxone: Rationale, Science, Misconceptions.
Velander, J. R. (2018) · PubMed Central · Cited by 43
NOP-Related Mechanisms in Substance Use Disorders
Ciccocioppo, R., Borruto, A. M., Domi, A., Teshima, K., Cannella, N., & Weiss, F. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_209 · Cited by 43
Initiating buprenorphine treatment for opioid use disorder during short‐term in‐patient ‘detoxification’: a randomized clinical trial
Stein, M. D., Herman, D. S., Conti, M. T., Anderson, B. J., & Bailey, G. L. (2019) · Addiction · doi:10.1111/add.14737 · Cited by 42
Scientific and political challenges in North America's first randomized controlled trial of heroin-assisted treatment for severe heroin addiction: Rationale and design of the NAOMI study
Oviedo‐Joekes, E., Nosyk, B., Marsh, D. C., Guh, D. P., Brissette, S., Gartry, C. C., Krausz, M. R., Anis, A. H., & Schechter, M. T. (2009) · Clinical Trials · doi:10.1177/1740774509105222 · Cited by 41
Urinary Detection Times and Metabolite/Parent Compound Ratios After a Single Dose of Buprenorphine
Kronstrand, R., Nyström, I., Andersson, M., Gunnarsson, L., Hägg, S., Josefsson, M., & Ahlner, J. (2008) · Journal of Analytical Toxicology · doi:10.1093/jat/32.8.586 · Cited by 42
Opioid substitution and antagonist therapy trials exclude the common addiction patient: a systematic review and analysis of eligibility criteria
Dennis, B. B., Roshanov, P. S., Naji, L., Bawor, M., Paul, J., Plater, C., Paré, G., Worster, A., Varenbut, M., Daiter, J., et al. (2015) · Trials · doi:10.1186/s13063-015-0942-4 · Cited by 41
Impact of Fentanyl Use on Buprenorphine Treatment Retention and Opioid Abstinence
Wakeman, S. E., Chang, Y., Regan, S., Yu, L., Flood, J. G., Metlay, J. P., & Rigotti, N. A. (2018) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000486 · Cited by 42
Mood and neuroendocrine response to a chemical stressor, metyrapone, in buprenorphine-maintained heroin dependence
Kakko, J., von Wachenfeldt, J., Svanborg, K. D., Lidström, J., Barr, C. S., & Heilig, M. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.001 · Cited by 41
Self-citation
Methadone Medical Maintenance: An Early 21st-Century Perspective
Novick, D. M., Salsitz, E. A., Joseph, H., & Kreek, M. J. (2015) · Journal of Addictive Diseases · doi:10.1080/10550887.2015.1059225 · Cited by 41
Self-citation
A systematic review of sex differences in treatment outcomes among people with opioid use disorder receiving buprenorphine maintenance versus other treatment conditions
Ling, S., Mangaoil, R. A., Cleverley, K., Sproule, B. A., & Puts, M. T. E. (2019) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2019.02.007 · Cited by 41
Beyond Buprenorphine: Models of Follow-up Care for Opioid Use Disorder in the Emergeny Department
Martin, A., Butler, K., Chavez, T. J., Herring, A. A., Wakeman, S. E., Hayes, B. D., & Raja, A. S. (2020) · Western Journal of Emergency Medicine · doi:10.5811/westjem.2020.7.46079 · Cited by 41
Professional education to reduce provider stigma toward harm reduction and pharmacotherapy
Sulzer, S. H., Prevedel, S. M., Barrett, T. S., Voss, M. W., Manning, C., & Madden, E. F. (2021) · Drugs Education Prevention and Policy · doi:10.1080/09687637.2021.1936457 · Cited by 41
Outcomes of Buprenorphine Maintenance in Office-Based Practice
Magura, S., Lee, S. J., Salsitz, E. A., Kolodny, A., Whitley, S. D., Taubes, T., Seewald, R., Joseph, H., Kayman, D. J., Fong, C., et al. (2007) · Journal of Addictive Diseases · doi:10.1300/j069v26n02_03 · Cited by 41
Trends and Characteristics of Buprenorphine-Involved Overdose Deaths Prior to and During the COVID-19 Pandemic
Tanz, L. J., Jones, C. M., Davis, N. L., Compton, W. M., Baldwin, G. T., Han, B., & Volkow, N. D. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.51856 · Cited by 40
Opioid overdose and the power of old myths: What we thought we knew, what we do know and why it matters
Darke, S. G. (2014) · Drug and Alcohol Review · doi:10.1111/dar.12108 · Cited by 39
Effects of drug substitution programs on offending among drug-addicts
Egli, N. M., Pina, M., Christensen, P. S., Aebi, M. F., & Killias, M. (2009) · Campbell Systematic Reviews · doi:10.4073/csr.2009.3 · Cited by 39
Opioid agonist therapy trajectories among street entrenched youth in the context of a public health crisis
Giang, V., Thulien, M., McNeil, R., Sedgemore, K., Anderson, H., & Fast, D. (2020) · SSM - Population Health · doi:10.1016/j.ssmph.2020.100609 · Cited by 37
A multi-level analysis of counselor attitudes toward the use of buprenorphine in substance abuse treatment
Rieckmann, T. R., Kovas, A. E., McFarland, B. H., & Abraham, A. J. (2011) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2011.05.005 · Cited by 38
User-centred clinical decision support to implement emergency department-initiated buprenorphine for opioid use disorder: protocol for the pragmatic group randomised EMBED trial
Melnick, E. R., Jeffery, M. M., Dziura, J. D., Mao, J. A., Hess, E. P., Platts‐Mills, T. F., Solad, Y., Paek, H., Martel, S. H., Patel, M. D., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-028488 · Cited by 38
Optimal dose of buprenorphine in opioid use disorder treatment: a review of pharmacodynamic and efficacy data
Hjelmström, P., Nordbeck, E. B., & Tiberg, F. (2020) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2019.1706552 · Cited by 39
Buprenorphine-naloxone versus methadone maintenance therapy: A randomised double-blind trial with opioid-dependent patients
Kamien, J. B., Branstetter, S. A., & Amass, L. (2008) · Heroin addiction and related clinical problems · Cited by 38
The impact of a reduction in drug supply on demand for and compliance with treatment for drug dependence
Degenhardt, L. J., Conroy, E., Day, C., Gilmour, S., & Hall, W. (2005) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2005.01.018 · Cited by 37
Primary care patient characteristics associated with completion of 6-month buprenorphine treatment
Neumann, A. M., Blondell, R. D., Azadfard, M., Nathan, G., & Homish, G. G. (2013) · Addictive Behaviors · doi:10.1016/j.addbeh.2013.07.007 · Cited by 37
Buprenorphine/Naloxone for opioid dependence: clinical practice guideline.
Handford, C. D., Kahan, M., Srivastava, A., Cirone, S., & Palda, V. A. (2011) · Cited by 36
A call for consensus in defining efficacy in clinical trials for opioid addiction: combined results from a systematic review and qualitative study in patients receiving pharmacological assisted therapy for opioid use disorder
Dennis, B. B., Sanger, N., Bawor, M., Naji, L., Plater, C., Worster, A., Woo, J., Bhalerao, A., Baptist-Mohseni, N., Hillmer, A., et al. (2020) · Trials · doi:10.1186/s13063-019-3995-y · Cited by 37
Mobilizing pharmacists to address the opioid crisis: A joint opinion of the ambulatory care and adult medicine practice and research networks of the American College of Clinical Pharmacy
Coon, S. A., Hill, L. G., Hutchison, R. W., Arnold, L. M., Jarrett, J. B., Ottney, A. R., Oung, A. B., Painter, N. A., Smith, M. A., Stranges, P. M., et al. (2020) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.1331 · Cited by 36
Buprenorphine for opioid dependence
Ling, W. W. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.26 · Cited by 35
Age disparities in six-month treatment retention for opioid use disorder
Mintz, C. M., Presnall, N. J., Sahrmann, J. M., Borodovsky, J. T., Glaser, P. E. A., Bierut, L. J., & Grucza, R. A. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.108130 · Cited by 35
Participant Characteristics and HIV Risk Behaviors Among Individuals Entering Integrated Buprenorphine/Naloxone and HIV Care
Chaudhry, A. A., Botsko, M., Weiss, L., Egan, J. E., Mitty, J. A., Estrada, B. D., Lucas, G. M., Woodson, T., Flanigan, T., & Fiellin, D. A. (2011) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e318209d3b9 · Cited by 35
Buprenorphine Initiation and Linkage to Outpatient Buprenorphine do not Reduce Frequency of Injection Opiate Use Following Hospitalization
Cushman, P. A., Liebschutz, J. M., Anderson, B. J., Moreau, M. R., & Stein, M. D. (2016) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2016.06.003 · Cited by 35
Treatment of Adolescent Opioid Dependence
Fiellin, D. A. (2008) · JAMA · doi:10.1001/jama.2008.567 · Cited by 35
Computerized Clinical Decision Support System for Emergency Department–Initiated Buprenorphine for Opioid Use Disorder: User-Centered Design
Ray, J. M., Ahmed, O. M., Solad, Y., Maleska, M., Martel, S. H., Jeffery, M. M., Platts‐Mills, T. F., Hess, E. P., D’Onofrio, G., & Melnick, E. R. (2019) · JMIR Human Factors · doi:10.2196/13121 · Cited by 35
Concerns about injectable naltrexone for opioid dependence
Wolfe, D., Carrieri, P., Dasgupta, N., WODAK, A. D., Newman, R. G., & Bruce, R. D. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62056-9 · Cited by 34
Can the Chronic Administration of the Combination of Buprenorphine and Naloxone Block Dopaminergic Activity Causing Anti-reward and Relapse Potential?
Blum, K., Chen, T. J. H., Bailey, J., Bowirrat, A., Femino, J., Chen, A. L., Simpatico, T. A., Morse, S. A., Giordano, J., Damle, U. J., et al. (2011) · Molecular Neurobiology · doi:10.1007/s12035-011-8206-0 · Cited by 35
Effectiveness and cost-effectiveness of unsupervised buprenorphine-naloxone for the treatment of heroin dependence in a randomized waitlist controlled trial
Dunlop, A. J., Brown, A. L., Oldmeadow, C. J., Harris, A., Gill, A. J., Sadler, C., Ribbons, K., Attia, J., Barker, D., Ghijben, P., et al. (2017) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2017.01.016 · Cited by 32
Neuropharmacological and Neurogenetic Correlates of Opioid Use Disorder (OUD) As a Function of Ethnicity: Relevance to Precision Addiction Medicine
Abijo, T., Blum, K., & Gondré‐Lewis, M. C. (2019) · Current Neuropharmacology · doi:10.2174/1570159x17666191118125702 · Cited by 33
Factors Associated With Adherence to Methylphenidate Treatment in Adult Patients With Attention-Deficit/Hyperactivity Disorder and Substance Use Disorders
Skoglund, C. B., Brandt, L., Almqvist, C., D'Onofrio, B. M., Konstenius, M., Franck, J., & Larsson, H. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000501 · Cited by 36
Pharmacological treatments for opiate and alcohol addiction: A historical perspective of the last 50 years
Blanco-Gandía, M. C., & Rodríguez‐Arias, M. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.08.007 · Cited by 35
Poly-substance use and antisocial personality traits at admission predict cumulative retention in a buprenorphine programme with mandatory work and high compliance profile
Öhlin, L., Hesse, M., Fridell, M., & Tätting, P. (2011) · BMC Psychiatry · doi:10.1186/1471-244x-11-81 · Cited by 32
A machine learning based two-stage clinical decision support system for predicting patients’ discontinuation from opioid use disorder treatment: retrospective observational study
Hasan, M. M., Young, G. J., Shi, J., Mohite, P., Young, L. D., Weiner, S. G., & Noor‐E‐Alam, M. (2021) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-021-01692-7 · Cited by 33
Management of women treated with buprenorphine during pregnancy
Alto, W. A., & O’Connor, A. B. (2011) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2011.04.001 · Cited by 31
A scalable, automated warm handoff from the emergency department to community sites offering continued medication for opioid use disorder: Lessons learned from the EMBED trial stakeholders
Ahmed, O. M., Mao, J. A., Holt, S. R., Hawk, K. F., D’Onofrio, G., Martel, S. H., & Melnick, E. R. (2019) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2019.05.006 · Cited by 31
Mortality in Opioid-Maintained Patients after Release from an Addiction Clinic
Bauer, S. M., Loipl, R., Jagsch, R., Gruber, D., Risser, D., Thau, K., & Fischer, G. (2008) · European Addiction Research · doi:10.1159/000113722 · Cited by 31
Medicaid Coverage of Methadone Maintenance and the Use of Opioid Agonist Therapy Among Pregnant Women in Specialty Treatment
Bachhuber, M. A., Mehta, P., Faherty, L. J., & Saloner, B. K. (2017) · Medical Care · doi:10.1097/mlr.0000000000000803 · Cited by 31
Feasibility and acceptability of a digital health intervention to promote engagement in and adherence to medication for opioid use disorder
Langdon, K. J., Scherzer, C. R., Ramsey, S. E., Carey, K. B., Rich, J. D., & Ranney, M. L. (2021) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2021.108538 · Cited by 30
Buprenorphine infrequently found in fatal overdose in New York City
Paone, D., Tuazon, E. D., Stajić, M., Sampson, B. A., Allen, B., Mantha, S., & Kunins, H. V. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.08.007 · Cited by 30
The leading neighborhood-level predictors of drug overdose: A mixed machine learning and spatial approach
Bozorgi, P., Porter, D. E., Eberth, J. M., Eidson, J. P., & Karami, A. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.109143 · Cited by 29
Very early disengagement and subsequent re-engagement in primary care Office Based Opioid Treatment (OBOT) with buprenorphine
Hui, D. S. C., Weinstein, Z., Cheng, D. M., Quinn, E. K., Kim, H. W., LaBelle, C. T., & Samet, J. H. (2017) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2017.05.010 · Cited by 28
Buprenorphine-Containing Treatments
Robinson, S. E. (2006) · CNS Drugs · doi:10.2165/00023210-200620090-00001 · Cited by 28
Management of opioid addiction with buprenorphine: French history and current management
Bourkaib, M., Poloméni, P., & Schwan, R. (2014) · International Journal of General Medicine · doi:10.2147/ijgm.s53170 · Cited by 27
Adoption of Medications in Substance Abuse Treatment: Priorities and Strategies of Single State Authorities
Rieckmann, T. R., Kovas, A. E., & Rutkowski, B. A. (2010) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2010.10400546 · Cited by 27
Self-reported Sleep Improvement in Buprenorphine MAT (Medication Assisted Treatment) Population.
Zheng, W. H., Wakim, R., Geary, R., Lander, L. R., Sj, W., Xiao, M., & Sullivan, C. R. (2016) · PubMed · Cited by 26
Extended‐release naltrexone (XR‐NTX) for opioid use disorder in clinical practice: Vivitrol's Cost and Treatment Outcomes Registry
Saxon, A. J., Akerman, S. C., Liu, C., Sullivan, M. A., Silverman, B. L., & Vocci, F. J. (2018) · Addiction · doi:10.1111/add.14199 · Cited by 30
Recent Advances in the Potential of Positive Allosteric Modulators of the GABAB Receptor to Treat Alcohol Use Disorder
Augier, E. (2021) · Alcohol and Alcoholism · doi:10.1093/alcalc/agab003 · Cited by 29
Analysis of Stimulant Prescriptions and Drug-Related Poisoning Risk Among Persons Receiving Buprenorphine Treatment for Opioid Use Disorder
Mintz, C. M., Xu, K. Y., Presnall, N. J., Hartz, S. M., LEVIN, F. R., Scherrer, J. F., Bierut, L. J., & Grucza, R. A. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.11634 · Cited by 26
Virtual opioid agonist treatment: Alberta’s virtual opioid dependency program and outcomes
Day, N., Wass, M., & Smith, K. (2022) · Addiction Science & Clinical Practice · doi:10.1186/s13722-022-00323-4 · Cited by 26
Turning the Clock Ahead: Potential Preclinical and Clinical Neuropharmacological Targets for Alcohol Dependence
Leggio, L., Cardone, S., Ferrulli, A., Kenna, G. A., Diana, M., Swift, R. M., & Addolorato, G. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210791516369 · Cited by 26
Buprenorphine use and courses of care for opioid use disorder treatment within the Veterans Health Administration
Gordon, A. J., Saxon, A. J., Kertesz, S. G., Wyse, J. J. B., Manhapra, A., Lin, L. A., Chen, W., Hansen, J., Pinnell, D., Huynh, T., et al. (2023) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2023.109902 · Cited by 25
Using buprenorphine to facilitate entry into residential therapeutic community rehabilitation
Collins, E. D., Horton, T. L., Reinke, K., Amass, L., & Nunes, E. V. (2006) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2006.03.018 · Cited by 25
Socio-demographic Profile and Help-seeking Behaviour of Buprenorphine Abusers in Singapore
Winslow, M., Ng, W.-L., Mythily, S., Song, G., & Yiong, H.-C. (2006) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.v35n7p451 · Cited by 25
Mindfulness Training vs Recovery Support for Opioid Use, Craving, and Anxiety During Buprenorphine Treatment
Schuman‐Olivier, Z., Goodman, H., Rosansky, J. A., Fredericksen, A. K., Barria, J., Parry, G. J., Sokol, R. G., Gardiner, P. M., Cook, B. L., & Weiss, R. D. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.54950 · Cited by 24
Reversible brain white matter microstructure changes in heroin addicts: a longitudinal study
Wang, X., Yu, R., Zhou, X., Liao, Y., Tang, J., Liu, T., Shan, B., & Hao, W. (2011) · Addiction Biology · doi:10.1111/j.1369-1600.2011.00316.x · Cited by 23
Development and implementation of a physician-pharmacist collaborative practice model for provision and management of buprenorphine/naloxone
Mailloux, L. M., Haas, M. T., Larew, J., & DeJongh, B. M. (2021) · Mental Health Clinician · doi:10.9740/mhc.2021.01.035 · Cited by 23
Guidance for the use of substitute prescribing in the treatment of opioid dependence in primary care.
Ford, C., Halliday, K., Lawson, E., & Moxon-Browne, E. P. (2011) · Cited by 23
The clinical use of buprenorphine in opiate addiction: evidence and practice
Law, F. D., Myles, J. S., Daglish, M. R. C., & Nutt, D. (2004) · Acta Neuropsychiatrica · doi:10.1111/j.0924-2708.2004.00095.x · Cited by 22
Opioid overdose survivors: Medications for opioid use disorder and risk of repeat overdose in Medicaid patients
Crystal, S., Nowels, M., Samples, H., Olfson, M., Williams, A. R., & Treitler, P. C. (2022) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2022.109269 · Cited by 22
More beds are not the answer: transforming detoxification units into medication induction centers to address the opioid epidemic
Friedmann, P. D., & Suzuki, J. (2017) · Addiction Science & Clinical Practice · doi:10.1186/s13722-017-0092-y · Cited by 22
Changes in fentanyl demand following naltrexone, morphine, and buprenorphine in male rats
Hammerslag, L. R., Hofford, R. S., Kang, Q., Kryscio, R. J., Beckmann, J. S., & Bardo, M. T. (2019) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2019.107804 · Cited by 21
Brain magnetic resonance imaging of infants exposed prenatally to buprenorphine
Kahila, H. K., Kivitie‐Kallio, S., Halmesmäki, E., Valanne, L. K., & Autti, T. H. (2007) · Acta Radiologica · doi:10.1080/02841850601100875 · Cited by 22
Predictors of Outcome During a 6-Month Follow-Up Among Heroin Dependent Patients Receiving Buprenorphine/Naloxone Maintenance Treatment
Evren, C., Karabulut, V., Can, Y., Bozkurt, M., Umut, G., & Evren, B. (2014) · Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology · doi:10.5455/bcp.20140310072258 · Cited by 24

Authors: Kakko, J., Svanborg, K. D., Kreek, M. J., & Heilig, M.
Affiliations: Karolinska Institutet (SE)
Rockefeller University (US)
Corresponding author: Heilig, Markus
ORCID: Kreek, Mary Jeanne
Heilig, Markus
Venue: The Lancet
Publisher: Elsevier BV
Published: 2003-02
Volume: 361
Issue: 9358
Pages: 662-668
ISSN: 0099-5355 (ISSN-L)
0140-6736
DOI: 10.1016/s0140-6736(03)12600-1
OpenAlex: W2171737529
Cited by: 466
References: 32
Citations by year: 2026: 4 · 2025: 15 · 2024: 13 · 2023: 22 · 2022: 18 · 2021: 27 · 2020: 27 · 2019: 29 · 2018: 26 · 2017: 20 · 2016: 15 · 2015: 25 · 2014: 17 · 2013: 18 · 2012: 19
FWCI: 17.61
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The Lancet (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health
U.S. Public Health Service (P-50-05130, K05 00049)
Topics: Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
Keywords: buprenorphine, heroin addiction, relapse prevention, treatment retention, social functioning, group cognitive behavioral therapy, psychosocial interventions, urine drug testing, opioid use disorder, sublingual buprenorphine
MeSH terms: Adult, Buprenorphine, Counseling, Female, Heroin Dependence, Humans, Male, Narcotic Antagonists, Psychotherapy, Group, Severity of Illness Index, Sweden, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks